Thanks for clarifying and I completely agree with your line of thought. I too think that a positive Phase 2 result in UF will make NBIX a very compelling buyout opportunity. The TD indication is really an extra that isn't being given any value right now. However, I love the design of their new trial as it's enrolling people with other ailments such as mood disorders and schiz...I imagine some of the secondary outcome measures will look for improvement in these conditions. If that is seen then watch out...we could have an awesome candidate here. I temper that a little only because I've a longtime CNS investor and it's tough to find new candidates. However, NBIX has been at this for a really long time so they have as good a shot as anyone. Would love to see NBIX get back to the glory days....I was in it then btw. This was one of my biggest winners....I was in for all the wrong reasons (loved their CRF program) but sometimes it's better to be lucky than good and that was one of those times!